Letter to the Editor: Low Molecular Weight Heparins

Clinical and Applied Thrombosis/Hemostasis

Volumn 2, Issue 4, 1996, Pages 292-293

  Von Tempelhoff, G F ^a   Wolf, H ^a   Herrle, B ^a   Hojnacki, B ^a   Heilmann, L ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84996156969     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969600200412     Document Type: Article

References (6)

1. Goodwin. Use of low molecular weight heparins in malignancy-related thromboembolic disorders: a clinical review. Clinical and Applied Thrombosis/Hematosis 1996; 2(Suppl. 1):28-34.
2. Zacharski LR, Costantini V. Blood coagulation activation in cancer: challenges for cancer treatment. Hämostaseologie 1995;15: 14.
3. Clarke-Pearson DL, Coleman RE, Synan IS, et al. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 1983; 145: 606.
4. Heilmann L., von Tempelhoff G-F, Herrle B., et al. A prospective randomized trial of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) in patients with gynecologic cancer. Thromb Haemost 1995; 73 (Suppl. 1):974.
5. von Tempelhoff G-F, Dietrich M., Schneider D., Wolf H., Heilmann L. A prospective randomized study on the perioperative treatment with either low molecular weight heparin or unfractionated standard heparin for thrombosis prophylaxis in patients with gynecologic malignancy. Ann Hematol 1996;(Suppl. 1)72: 209.
6. Kakkar VV, Murray Wjg. Efficacy and safety of low molecular weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a cooperative study. Br J Surg 1985; 72: 786.